BC
Birchview Capital Portfolio holdings
AUM
$101M
This Quarter Return
-0.71%
1 Year Return
+34.62%
3 Year Return
+103.2%
5 Year Return
+107.72%
10 Year Return
+352.1%
AUM
$108M
AUM Growth
+$108M
(-12%)
Cap. Flow
-$5.67M
Cap. Flow
% of AUM
-5.24%
Top 10 Holdings %
Top 10 Hldgs %
67.6%
Holding
63
New
4
Increased
7
Reduced
9
Closed
3
Top Buys
| 1 |
Corcept Therapeutics
CORT
|
$780K |
| 2 |
Prothena Corp
PRTA
|
$702K |
| 3 |
Exxon Mobil
XOM
|
$673K |
| 4 |
Biodesix
BDSX
|
$531K |
| 5 |
Castle Biosciences
CSTL
|
$435K |
Top Sells
| 1 |
Neurocrine Biosciences
NBIX
|
$4.82M |
| 2 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$1.69M |
| 3 |
PXD
Pioneer Natural Resource Co.
PXD
|
$998K |
| 4 |
Bristol-Myers Squibb
BMY
|
$639K |
| 5 |
Elutia
ELUT
|
$514K |
Sector Composition
| 1 | Healthcare | 94.57% |
| 2 | Energy | 5.43% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$96B
| $28.6M | 26.42% | 688,218 -15,388 | -2% | -$639K |
|
|
2
Biodesix
BDSX
$62.6M
| $8.7M | 8.04% | 5,696,113 +347,840 | +7% | +$531K |
|
|
3
Elutia
ELUT
$96.7M
| $7.7M | 7.11% | 1,551,655 -103,529 | -6% | -$514K |
|
|
4
Neurocrine Biosciences
NBIX
$13.8B
| $5.82M | 5.37% | 42,240 -35,000 | -45% | -$4.82M |
|
|
SILK
5
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $4.27M | 3.95% | 158,094 | – | – |
|
|
6
Prothena Corp
PRTA
$441M
| $4.2M | 3.88% | 203,574 +34,000 | +20% | +$702K |
|
7
Acadia Pharmaceuticals
ACAD
$4.38B
| $4.07M | 3.76% | 250,400 | – | – |
|
8
Ovintiv
OVV
$10.8B
| $3.48M | 3.21% | 74,200 -10,000 | -12% | -$469K |
|
9
United Therapeutics
UTHR
$13.8B
| $3.19M | 2.94% | 10,000 -1,000 | -9% | -$319K |
|
10
Harrow
HROW
$1.44B
| $3.13M | 2.9% | 150,000 | – | – |
|
11
Stoke Therapeutics
STOK
$1.08B
| $2.84M | 2.62% | 210,000 | – | – |
|
12
Phreesia
PHR
$1.88B
| $2.43M | 2.25% | 114,700 | – | – |
|
|
13
Corcept Therapeutics
CORT
$7.35B
| $2.4M | 2.22% | 74,000 +24,000 | +48% | +$780K |
|
14
QuidelOrtho
QDEL
$1.95B
| $2.25M | 2.08% | 67,619 +2,416 | +4% | +$80.3K |
|
15
Masimo
MASI
$7.59B
| $1.92M | 1.78% | 15,280 | – | – |
|
16
Foghorn Therapeutics
FHTX
$286M
| $1.85M | 1.71% | 320,930 | – | – |
|
|
ETRN
17
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
| $1.73M | 1.6% | 133,050 | – | – |
|
18
Protagonist Therapeutics
PTGX
$3.67B
| $1.66M | 1.54% | 48,000 | – | – |
|
19
Axogen
AXGN
$743M
| $1.43M | 1.32% | 197,000 +24,000 | +14% | +$174K |
|
20
DocGo
DCGO
$153M
| $1.42M | 1.31% | 460,000 | – | – |
|
21
Alkermes
ALKS
$4.78B
| $1.21M | 1.11% | 50,000 | – | – |
|
22
Travere Therapeutics
TVTX
$1.56B
| $1M | 0.93% | 122,000 | – | – |
|
23
Alphatec Holdings
ATEC
$2.35B
| $920K | 0.85% | 88,000 | – | – |
|
|
24
Castle Biosciences
CSTL
$696M
| $740K | 0.68% | 34,000 +20,000 | +143% | +$435K |
|
|
25
Exxon Mobil
XOM
$487B
| $673K | 0.62% | +5,849 | New | +$673K |
|